Inhibikase Therapeutics (IKT) Misses Q3 EPS by 65c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q3 EPS of ($0.65).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cinema United: issues joint letter to state AGs and Paramount
- OpenAI pauses frontier model training to strengthen safeguards
- Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
